Abstract 101P
Background
Chemoresistance is a major reason for treatment failure and results in poor prognosis in patients with advanced colorectal cancer (CRC). Hypoxia-inducible factor-1 (HIF1-α) is a regulator of the transcriptional response to oxygen deprivation in cancer cells and activates the transcription of genes that are involved in angiogenesis, cell survival and invasion. However, the effect of HIF1-α activation on oxaliplatin resistance in CRC is unclear. This study aimed to investigate the effects and potential mechanism of HIF1-α on oxaliplatin resistance in CRC.
Methods
Oxaliplatin-resistant cells were generated from HCT116 cells. Cell Counting Kit-8, flow cytometry, Transwell assay were used to compare the characteristics of oxaliplatin resistant HCT116 (HCT116_OxR) cells and the corresponding parental HCT116 cells. The expression of HIF1-α, extracellular signal-related kinase (ERK), and transforming growth factor β (TGFβ) were confirmed by RT-PCR and western blotting in HCT116_OxR and HCT116 cells. Next, we evaluated the combination efficacy of inhibitors of HIF1-α (YC-1), ERK (Ravoxertinib), and TGFβ1 (SB431542) with oxaliplatin by in vitro and in vivo experiments.
Results
We found that cell viability of HCT116_OxR was higher than that in parental cells in the presence of oxaliplatin. The relative expression of HIF1-α was significantly increased in HCT116_OxR cells compared with the parental HCT116 cells. Downregulation of HIF1-α in HCT116_OxR cells increased oxaliplatin sensitivity, and diminished cell survival and invasion. Significantly, ERK signaling in HCT116_OxR cells is dependent on TGFβ1, promoting oxaliplatin resistance by activating HIF1-α. Inhibition of ERK by Ravoxertinib or TGFβ1 by SB431542 efficiently overcame oxaliplatin resistance in vitro and in vivo.
Conclusions
HIF1-α activation is regulated by TGFβ1/ERK axis in HCT116_OxR cells. Hence, HIF1-α, ERK, and TGFβ1 are potential therapeutic targets for overcoming oxaliplatin resistance in patients with CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session